丹麦绝经后重度骨质疏松女性中罗莫佐单抗的治疗模式:ROSES研究真实世界证据
该丹麦注册回顾性队列研究纳入2020年9月至2023年10月接受骨质疏松药物治疗的≥50岁女性149395例,分三组比较患者与处方者特征及罗莫佐单抗使用因素。罗莫佐单抗组622例更年轻、合并症和糖皮质激素使用比例更低,44.5%为初治,中位治疗转换时间350天,多数在11-15个月转换为唑来膦酸、阿仑膦酸钠或地舒单抗。
要点
- 罗莫佐单抗组患者较其他骨质疏松治疗组更年轻且合并症更少。
- 罗莫佐单抗组44.5%为初治患者,多数由二级内分泌专科启动治疗。
- 罗莫佐单抗中位治疗转换时间350天,多数在11-15个月转换。
核心结论
- 研究提供了丹麦全国范围内罗莫佐单抗使用患者与处方者特征及治疗模式的真实世界见解。
- 相当比例患者将罗莫佐单抗作为序贯治疗的首个药物,作者认为在高骨折风险患者中先用骨合成代谢药物、后用抗骨吸收药物仍有优化骨密度结局的机会。
- 在有15个月随访数据的罗莫佐单抗治疗患者中,多数被推定在记录治疗转换时已持续使用罗莫佐单抗11-15个月。
研究设计与样本
- 丹麦注册回顾性队列研究,纳入2020年9月至2023年10月接受骨质疏松药物治疗的≥50岁女性。
- 共纳入149395例患者,分为三组:罗莫佐单抗组(队列1,n=622)、近三年内有骨质疏松相关骨折并使用其他骨质疏松药物组(队列2,n=29021)、启动其他骨质疏松药物前三年内无骨质疏松相关骨折组(队列3,n=119752)。
- 报告患者与处方者特征、接受罗莫佐单抗及治疗转换的相关因素。
主要发现
- 队列1(n=622)较队列2(n=29021)和队列3(n=119752)更年轻,合并症比例和糖皮质激素使用比例更低。
- 队列1中277例(44.5%)为骨质疏松初治患者,多数从二级内分泌专科接受索引治疗。
- 从罗莫佐单抗启动至记录治疗转换的中位时间为350天,多数患者在11-15个月间转换。
- 转换去向为唑来膦酸(53.5%)、阿仑膦酸钠(18.9%)或地舒单抗(13.5%)。
关键数值与推荐
- 罗莫佐单抗组622例中277例(44.5%)为骨质疏松治疗初治。
- 罗莫佐单抗启动至记录治疗转换的中位时间为350天。
- 转换治疗中唑来膦酸占53.5%、阿仑膦酸钠占18.9%、地舒单抗占13.5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To describe patient and prescriber characteristics and factors associated with utilization of romosozumab in Denmark. METHODS: This registry‑based Danish retrospective cohort study comprised females aged ≥ 50 receiving osteoporosis medication from September 2020 - October 2023. Three cohorts were identified: those treated with romosozumab (cohort 1), those with osteoporosis‑related fracture within the last three years treated with other osteoporosis medications (cohort 2), and those without osteoporosis‑related fracture within three years prior to initiating other osteoporosis medications (cohort 3). Patient and prescriber characteristics are presented by cohort. Factors associated with receiving romosozumab and transition of treatment are reported. RESULTS: Overall, 149,395 patients were included. Cohort 1 (n = 622) was younger, had lower proportions of comorbidities and use of glucocorticoids than cohorts 2 (n = 29,021) and 3 (n = 119,752). In cohort 1, 277 patients (44.5%) were osteoporosis treatment‑naïve and the majority received their index treatment from secondary endocrinological care. The median duration from romosozumab initiation to a recorded treatment transition was 350 days; most patients transitioned between 11-15 months to zoledronate (53.5%), alendronate (18.9%), or denosumab (13.5%). CONCLUSION: This study provides real-world insight into patient and prescriber characteristics, and patterns and factors of romosozumab use across Denmark. Whilst a notable proportion of patients received romosozumab first in sequential therapy, there is still opportunity to optimize bone mineral density (BMD) outcomes with osteoanabolic agents used first, followed by an antiresorptive, in patients at high fracture risk. Of romosozumab-treated patients with 15 months follow-up data, most were assumed to continue romosozumab for 11-15 months when treatment transition was recorded. Real-world data from Danish registries were used to describe treatment patterns with romosozumab and other anti-osteoporosis treatments in postmenopausal women with osteoporosis. The study found romosozumab‑treated patients were younger and had fewer comorbidities than other osteoporosis patients. Among romosozumab-treated patients, 44.5% were treatment-naïve and most continued with romosozumab for 11-15 months.
引用
- Langdahl BL, Lorentzon M, Borgen TT, et al. Treatment patterns of romosozumab in postmenopausal women with severe osteoporosis in Denmark: findings from the ROmosozumab in Scandinavia real-world Evidence Study (ROSES). Osteoporos Int. 2025. PMID: 41258137. doi:10.1007/s00198-025-07756-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。